Aurinia Pharmaceuticals Completes Acquisition of Assets

Aurinia Pharmaceuticals Inc. completed an acquisition of assets effective May 11 2026 according to an 8-K filed that day with the SEC.

The filing discloses Item 2.01 Completion of Acquisition or Disposition of Assets and Item 9.01 Financial Statements and Exhibits. Aurinia Pharmaceuticals Inc. CIK 0001600620 is the filer. The primary source bundle supplies no further detail on the counterparty the exact assets transferred or the consideration paid in cash stock or a mix.

The transaction shifts ownership of the identified assets from the seller to Aurinia. Prior to closing the assets sat on the counterparty balance sheet. Post-closing Aurinia assumes operational control and integrates them into its pharmaceutical portfolio. The change took effect on the filing date of May 11 2026.

Downstream the company must incorporate the acquired assets into its next quarterly or annual financial statements. Item 9.01 requires exhibits that include the purchase agreement and any required pro forma financial information. These exhibits become part of the public record immediately.

The seller may face parallel reporting obligations if it is a public company. Contractual milestones such as post-closing adjustments earn-out payments or transition services now activate per the terms appended to the filing. Standard SEC rules require any material subsequent events tied to the deal to be disclosed in future 8-K or 10-Q filings.

This marks the latest corporate filing by Aurinia Pharmaceuticals Inc. detailing a change in its asset base. The company last appeared in SEC records for routine disclosures prior to this transaction. Public companies file Form 8-K within four business days of material events under Item 2.01 to notify investors and maintain compliance with Exchange Act reporting obligations.

Per the SEC EDGAR archive the filing carries accession number 0001140361-26-020402 and was submitted on May 11 2026.